Table 1.
Studies included in the review and main study characteristics.
| PMID | Author/year | Funding | Locale | Comparisons | Population | Cohorts | CE metric | PHI/NNV |
|---|---|---|---|---|---|---|---|---|
| 29297049 | Le and Rothberg (2018)21 | Independent | US | RZV vs no vaccination RZV vs ZVL |
ARDI-60+ | 60, 70, 80 | ICER | Not reported |
| 29958739 | You et al (2018)34 | Independent | CN (HK) | RZV vs no vaccination | ARDI-50+ | 50, 60, 70 | ICER | Not reported |
| 30017145 | Curran et al (2018)22 | Industry | US | RZV vs no vaccination RZV vs ZVL |
ARDI-50+ | 50, 60, 65, 70, 80 | ICER | Reported |
| 29987323 | Le and Rothberg (2018b)27 | Independent | US | RZV vs no vaccination RZV vs prior vaccination with ZVL |
ARDI-50+ | 50–59; 60/70/80 (ZVL vaccination) |
ICER | Not reported |
| 30518427 | de Boer et al (2018)29 | Independent | NL | RZV vs no vaccination ZVL vs no vaccination ZVL+boost vs no vaccination |
ARDI-50+ | 50, 60, 70, 80 | ICER | Reported |
| 30130448 | Van Oorschot et al (2019)26 | Industry | GE | RZV vs no vaccination | ARDI-60+ | 60+, 70+, 60, 65, 70 | ICER | Reported |
| 30625011 | Curran et al (2019)23 | Industry | US | RZV vs prior vaccination with ZVL | ARDI-60+ | 60+ | ICER | Not reported |
| 30608953 | You et al (2019)35 | Independent | CN (HK) | RZV vs no vaccination | ARDI-50+ | 50–80 (31 total) | ICER | Reported |
| 30776797 | Prosser et al (2019)24 | Independent | US | RZV vs no vaccination RZV vs ZVL RZV vs prior vaccination with ZVL ZVL vs no vaccination |
ARDI-50+ | 50–59, 60–69, 70–79, 80–89, 90–99, 60+ | ICER | Not reported |
| 30929219 | Shiragami et al (2019)33 | Industry | JP | RZV vs no vaccination | ARDI-65+ | 65+, 50+, 60+, 70+ | ICER | Not reported |
| 31153691 | Hoshi et al (2019)32 | Independent | JP | RZV vs no vaccination ZVL vs no vaccination |
ARDI-65+ | 65–84, 70–84, 75–84, 80-84 | ICER, NMB | Not reported |
| 31289726 | Carpenter et al (2019)25 | Independent | US | RZV vs no vaccination ZVL vs no vaccination |
ARDI-50+ | 50, 60, 70 | ICER | Not reported |
| 31451524 | Drolet et al (2019)20 | Independent | CA | RZV vs no vaccination ZVL vs no vaccination |
ARDI-50+ | 50, 60, 65, 70, 75, 80, 85 | ICER | Reported |
| 31250218 | McGirr et al (2019)26 | Industry | CA | RZV vs no vaccination RZV vs ZVL |
ARDI-60+ | 60+ | ICER | Reported |
| 34905463 | Curran et al (2021)28 | Industry | GE | RZV vs no vaccination | ARDI-50+ | 50, 60, 65, 70, 50+, 60+, 70+ | ICER | Reported |
| 35094374 | Pieters et al (2022)30 | Independent | BE | RZV vs no vaccination ZVL vs no vaccination ZVL+boost vs no vaccination |
ARDI-50+ | 50, 60, 70, 80, 85 | ICER | Reported |
| NA | Ortega-Sanchez (2021)18 | Independent | US | RZV vs no vaccination | IC-18+ | CDC: 19–29, 30–39, 40-49 GSK: 18-49 |
ICER | Reported |
| NA | Ultsch et al (2017)19 | Independent | GE | RZV vs no vaccination ZVL vs no vaccination |
ARDI-50+ | 60, 50, 55, 65, 70, 75, 80 | ICER | Reported |
Note: For each study, costs were represented in MV and benefits in QALY.
ARDI: age-related decline in immunity; CDC: Centers for Disease Control and Prevention; CE: cost-effectiveness; IC: immunocompromised; ICER: incremental cost-effectiveness ratio; MV: monetary value; NA: not applicable; NMB: net monetary benefit; NNV: number needed to vaccinate; PHI: public health impact; PMID: PubMed identifier; QALY: quality-adjusted life year; ZVL: zoster vaccine live.
Locale abbreviations: BE: Belgium; CA: Canada; CN: China; GE: Germany; HK: Hong-Kong; JP: Japan; NL: The Netherlands; US: United States.